TuisAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Vorige sluiting
$27,80
Dagwisseling
$27,11 - $28,23
Jaarwisseling
$22,24 - $45,99
Markkapitalisasie
1,59 mjd USD
Gemiddelde volume
1,41 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
The Motley Fool
1 uur gelede
Prediction: This Growth ETF Will Crush the S&P 500 Over the Next 10 Years
0,064%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 12,88 m | 43,69% |
Bedryfskoste | 41,27 m | 7,10% |
Netto inkomste | -103,43 m | -110,91% |
Netto winsgrens | -803,05 | -107,59% |
Wins per aandeel | -1,78 | -21,49% |
EBITDA | -115,50 m | -13,83% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 952,86 m | -5,17% |
Totale bates | 1,39 mjd | -22,66% |
Totale aanspreeklikheid | 101,38 m | -38,61% |
Totale ekwiteit | 1,28 mjd | — |
Uitstaande aandele | 58,31 m | — |
Prys om te bespreek | 1,26 | — |
Opbrengs op bates | -20,45% | — |
Opbrengs op kapitaal | -21,27% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -103,43 m | -110,91% |
Kontant van bedrywe | -88,15 m | -4,67% |
Kontant van beleggings | 95,56 m | -61,90% |
Kontant van finansiering | 4,44 m | 68,18% |
Netto kontantverandering | 11,84 m | -93,00% |
Beskikbare kontantvloei | -56,62 m | -1 769,96% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
487
